🇺🇸 TRELAGLIPTIN SUCCINATE in United States

14 US adverse-event reports

Marketing authorisation

FDA

  • Status: approved

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Cerebral Infarction — 2 reports (14.29%)
  2. Diabetes Mellitus — 2 reports (14.29%)
  3. Pemphigoid — 2 reports (14.29%)
  4. Renal Impairment — 2 reports (14.29%)
  5. Altered State Of Consciousness — 1 report (7.14%)
  6. Anaemia — 1 report (7.14%)
  7. Atrioventricular Block — 1 report (7.14%)
  8. Bacterial Prostatitis — 1 report (7.14%)
  9. Brain Stem Infarction — 1 report (7.14%)
  10. Cardiac Failure Congestive — 1 report (7.14%)

Source database →

TRELAGLIPTIN SUCCINATE in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Frequently asked questions

Is TRELAGLIPTIN SUCCINATE approved in United States?

Yes. FDA has authorised it.

Who is the marketing authorisation holder for TRELAGLIPTIN SUCCINATE in United States?

Marketing authorisation holder not available in our data.